Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III …
HL Levy, A Milanowski, A Chakrapani, M Cleary, P Lee… - The Lancet, 2007 - thelancet.com
HL Levy, A Milanowski, A Chakrapani, M Cleary, P Lee, FK Trefz, CB Whitley, F Feillet…
The Lancet, 2007•thelancet.comBackground Early and strict dietary management of phenylketonuria is the only option to
prevent mental retardation. We aimed to test the efficacy of sapropterin, a synthetic form of
tetrahydrobiopterin (BH4), for reduction of blood phenylalanine concentration. Methods We
enrolled 89 patients with phenylketonuria in a Phase III, multicentre, randomised, double-
blind, placebo-controlled trial. We randomly assigned 42 patients to receive oral doses of
sapropterin (10 mg/kg) and 47 patients to receive placebo, once daily for 6 weeks. The …
prevent mental retardation. We aimed to test the efficacy of sapropterin, a synthetic form of
tetrahydrobiopterin (BH4), for reduction of blood phenylalanine concentration. Methods We
enrolled 89 patients with phenylketonuria in a Phase III, multicentre, randomised, double-
blind, placebo-controlled trial. We randomly assigned 42 patients to receive oral doses of
sapropterin (10 mg/kg) and 47 patients to receive placebo, once daily for 6 weeks. The …
Background
Early and strict dietary management of phenylketonuria is the only option to prevent mental retardation. We aimed to test the efficacy of sapropterin, a synthetic form of tetrahydrobiopterin (BH4), for reduction of blood phenylalanine concentration.
Methods
We enrolled 89 patients with phenylketonuria in a Phase III, multicentre, randomised, double-blind, placebo-controlled trial. We randomly assigned 42 patients to receive oral doses of sapropterin (10 mg/kg) and 47 patients to receive placebo, once daily for 6 weeks. The primary endpoint was mean change from baseline in concentration of phenylalanine in blood after 6 weeks. Analysis was on an intention-to-treat basis. The study is registered with ClinicalTrials.gov, number NCT00104247.
Findings
88 of 89 enrolled patients received at least one dose of study drug, and 87 attended the week 6 visit. Mean age was 20 (SD 9·7) years. At baseline, mean concentration of phenylalanine in blood was 843 (300) μmol/L in patients assigned to receive sapropterin, and 888 (323) μmol/L in controls. After 6 weeks of treatment, patients given sapropterin had a decrease in mean blood phenylalanine of 236 (257) μmol/L, compared with a 3 (240) μmol/L increase in the placebo group (p<0·0001). After 6 weeks, 18/41 (44%) patients (95% CI 28–60) in the sapropterin group and 4/47 (9%) controls (95% CI 2–20) had a reduction in blood phenylalanine concentration of 30% or greater from baseline. Blood phenylalanine concentrations fell by about 200 μmol/L after 1 week in the sapropterin group and this reduction persisted for the remaining 5 weeks of the study (p<0·0001). 11/47 (23%) patients in the sapropterin group and 8/41 (20%) in the placebo group experienced adverse events that might have been drug-related (p=0·80). Upper respiratory tract infections were the most common disorder.
Interpretation
In some patients with phenylketonuria who are responsive to BH4, sapropterin treatment to reduce blood phenylalanine could be used as an adjunct to a restrictive low-phenylalanine diet, and might even replace the diet in some instances.
thelancet.com